Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy-Reference-Cited by-同舟云学术

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

Published:2023-04 Issue:4 Volume:29 Page:265.e1-265.e10
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Perl Alexander E.,Larson Richard A.^ORCID,Podoltsev Nikolai A.^ORCID,Strickland Stephen,Wang Eunice S.,Atallah Ehab,Schiller Gary J.,Martinelli Giovanni,Neubauer Andreas,Sierra Jorge^ORCID,Montesinos Pau,Recher Christian,Yoon Sung-Soo,Maeda Yoshinobu,Hosono Naoko^ORCID,Onozawa Masahiro^ORCID,Kato Takayasu,Kim Hee-Je^ORCID,Hasabou Nahla,Nuthethi Rishita,Tiu Ramon,Levis Mark J.

Funder

Astellas Pharma US Inc

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference24 articles.

1. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies;Kennedy;Front Oncol,2020

2. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

3. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis;Thiede;Blood,2002

4. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

5. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters–an analysis of 3082 patients;Bacher;Blood,2008

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy;Critical Reviews in Oncology/Hematology;2024-09

2. Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-08-30

3. Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years;Cancers;2024-08-17

4. How Could We Further Improve the Gilteritinib Maintenance After Allogeneic Hematopoietic Cell Transplantation in FLT3-Mutated AML?;Journal of Clinical Oncology;2024-07-31

5. Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report;Anti-Cancer Drugs;2024-07-08